Docetaxel-induced lung injury

Docetaxel is a chemotherapeutic agent commonly used against breast cancer, nonsmall cell lung cancer, gastric, prostate, head and neck cancer. Docetaxel- or taxane-induced interstitial lung disease (ILD) remains a relatively rare reported adverse event. Although rare, this complication remains an important event to identify and it carries a high mortality. We reported the case series of three patients who had pulmonary toxicity after docetaxel administration. Although literature has described patients progressing to respiratory failure and intubation, our patients responded well to steroid treatment and discontinued docetaxel administration.